Ladenburg downgraded Marinus Pharmaceuticals to Neutral from Buy without a price target following the company’s Q2 report. While the firm remains confident for October’s tuberous sclerosis complex, it is not confident investors will buy up Marinus to include $150M in equity by the end of 2025 and another $100M in 2026 to rally shares from here. The analyst cites balance sheet concerns for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNS:
- Marinus Pharmaceuticals reports Q2 EPS (63c), consensus (59c)
- Is MRNS a Buy, Before Earnings?
- Class Action Lawsuit against Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)
- Marinus Pharmaceuticals announces China NMPA approval for ganaxolone
- Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action – Contact Levi & Korsinsky LLP to Learn More